Compare SMCI & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMCI | ROIV |
|---|---|---|
| Founded | 1993 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1B | 20.7B |
| IPO Year | 2006 | 2021 |
| Metric | SMCI | ROIV |
|---|---|---|
| Price | $28.47 | $29.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $34.69 | $28.94 |
| AVG Volume (30 Days) | ★ 41.5M | 4.1M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $2,484,929,000.00 | $29,053,000.00 |
| Revenue This Year | $92.37 | N/A |
| Revenue Next Year | $21.47 | $744.61 |
| P/E Ratio | $32.99 | ★ N/A |
| Revenue Growth | ★ 11.68 | N/A |
| 52 Week Low | $19.48 | $10.01 |
| 52 Week High | $62.36 | $30.33 |
| Indicator | SMCI | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 64.59 |
| Support Level | $19.48 | $20.46 |
| Resistance Level | $33.17 | $30.33 |
| Average True Range (ATR) | 1.33 | 0.90 |
| MACD | 0.93 | 0.17 |
| Stochastic Oscillator | 91.09 | 91.84 |
Super Micro Computer Inc provides high-performance server technology services to cloud computing, data centers, high-performance computing, and the Internet of Things embedded markets. Its solutions include servers, storage systems, modular blade servers, workstations, full-rack scale solutions, networking devices, server sub-systems, and server management. These turn-key solutions are designed, developed, validated, and installed for AI datacenters. The company has one operating segment that develops and provides high-performance server solutions based upon a, modular and open-standard architecture. More than half of the firm's revenue is generated in the United States, with the rest coming from Europe, Asia, and other regions.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.